Drug Profile

HDM 2006

Alternative Names: HDM-2006

Latest Information Update: 07 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Huadong Medicine
Class Antineoplastics; Small molecules
Mechanism of Action Hematopoietic progenitor kinase 1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Solid tumours

Most Recent Events

25 Apr 2025 Pharmacokinetics, adverse events and pharmacodynamics data from preclinical trials in Cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
31 Dec 2024 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Metastatic disease, Late-stage disease) in China (PO) (CTR20244285)
01 Oct 2024 NMPA approves IND application for HDM 2006 in Solid tumours

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com